Published in Cancer Weekly, February 8th, 2005
This patent is part of a set of patents, both issued and pending, for the company's Wave technology that enhance its analytical sensitivity. Some of these technological advances are incorporated the current WAVE HS model and can also be incorporated into certain existing WAVE Systems as an upgrade package.
Collin D'Silva, Transgenomic's CEO, commented that "the introduction of our high-sensitivity detection technology has built...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.